

Emily B Ehlerding

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6773617/emily-b-ehlerding-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35
papers

1,475
citations

20
h-index

38
g-index

39
ext. papers

1,876
ext. citations

8.9
avg, IF

4.99
L-index

#	Paper	IF	Citations
35	NanoLuc: A Small Luciferase Is Brightening Up the Field of Bioluminescence. <i>Bioconjugate Chemistry</i> , 2016 , 27, 1175-1187	6.3	202
34	Theranostic nanoparticles. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1919-22	8.9	173
33	In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine. <i>ACS Nano</i> , 2015 , 9, 3926-34	16.7	137
32	Preclinical Pharmacokinetics and Biodistribution Studies of ⁸⁹ Zr-Labeled Pembrolizumab. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 162-168	8.9	110
31	Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 110-120	8.8	73
30	A Melanin-Based Natural Antioxidant Defense Nanosystem for Theranostic Application in Acute Kidney Injury. <i>Advanced Functional Materials</i> , 2019 , 29, 1904833	15.6	65
29	Molecular Imaging of Immunotherapy Targets in Cancer. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1487-1492	8.9	65
28	Noninvasive PET Imaging of T cells. <i>Trends in Cancer</i> , 2018 , 4, 359-373	12.5	63
27	ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer. <i>Molecular Pharmaceutics</i> , 2017 , 14, 1782-1789	5.6	62
26	Chelator-Free Radiolabeling of Nanographene: Breaking the Stereotype of Chelation. <i>Angewandte Chemie - International Edition</i> , 2017 , 56, 2889-2892	16.4	53
25	CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody. <i>Theranostics</i> , 2016 , 6, 1918-33	12.1	46
24	Multimodality Imaging Agents with PET as the Fundamental Pillar. <i>Angewandte Chemie - International Edition</i> , 2019 , 58, 2570-2579	16.4	40
23	Aptamer-Conjugated Framework Nucleic Acids for the Repair of Cerebral Ischemia-Reperfusion Injury. <i>Nano Letters</i> , 2019 , 19, 7334-7341	11.5	31
22	CD146-Targeted Multimodal Image-Guided Photoimmunotherapy of Melanoma. <i>Advanced Science</i> , 2019 , 6, 1801237	13.6	28
21	PET Imaging of Receptor Tyrosine Kinases in Cancer. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 1625-1636	6.1	27
20	Chelator-Free Labeling of Metal Oxide Nanostructures with Zirconium-89 for Positron Emission Tomography Imaging. <i>ACS Nano</i> , 2017 , 11, 12193-12201	16.7	27
19	Site-Specific Immuno-PET Tracer to Image PD-L1. <i>Molecular Pharmaceutics</i> , 2019 , 16, 2028-2036	5.6	24

18	Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 1296-1305	8.8	23
17	Molecular imaging of T cells: diabetes and beyond. <i>Advanced Drug Delivery Reviews</i> , 2019 , 139, 16-31	18.5	21
16	Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with Zr-Df-Atezolizumab. <i>Bioconjugate Chemistry</i> , 2019 , 30, 1434-1441	6.3	20
15	Dual-Targeted Molecular Imaging of Cancer. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 390-395	8.9	20
14	Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models. <i>American Journal of Cancer Research</i> , 2019 , 9, 53-63	4.4	18
13	CD38 as a PET Imaging Target in Lung Cancer. <i>Molecular Pharmaceutics</i> , 2017 , 14, 2400-2406	5.6	17
12	PET and SPECT imaging of melanoma: the state of the art. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 132-150	8.8	16
11	Targeting angiogenesis for radioimmunotherapy with a Lu-labeled antibody. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 123-131	8.8	15
10	Antibody-Based Tracers for PET/SPECT Imaging of Chronic Inflammatory Diseases. <i>ChemBioChem</i> , 2019 , 20, 422-436	3.8	13
9	Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics. <i>Molecular Pharmaceutics</i> , 2020 , 17, 1697-1705	5.6	12
8	Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models. <i>Molecular Pharmaceutics</i> , 2018 , 15, 1627-1634	5.6	11
7	Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection. <i>American Journal of Cancer Research</i> , 2019 , 9, 1454-1468	4.4	10
6	Chelator-Free Radiolabeling of Nanographene: Breaking the Stereotype of Chelation. <i>Angewandte Chemie</i> , 2017 , 129, 2935-2938	3.6	9
5	ImmunoPET imaging of CD38 expression in hepatocellular carcinoma using Cu-labeled daratumumab. <i>American Journal of Translational Research (discontinued)</i> , 2019 , 11, 6007-6015	3	7
4	Harnessing the Power of Molecular Imaging for Precision Medicine. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 171-2	8.9	6
3	Smaller Agents for Larger Therapeutic Indices: Nanoscale Brachytherapy with ¹⁷⁷ Lu-Labeled Gold Nanoparticles. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 834-5	8.9	4
2	Multimodale Kontrastmittel für die kombinierte Positronenemissionstomographie. <i>Angewandte Chemie</i> , 2019 , 131, 2592-2602	3.6	3
1	Imaging the Biodistribution and Performance of Transplanted Stem Cells with PET. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1331-2	8.9	3

